# Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients

> **NCT00957060** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 400 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GLIMEPIRIDE (HOE490)
- **DRUG:** SITAGLIPTIN

## Key facts

- **NCT ID:** NCT00957060
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2010-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957060, "Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00957060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*